Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC)Daniele Cretella(University of Parma)DSpaceUnipr (University of Parma)January 1, 2015Cited by 0SaveCiteExport RISWatch citationsRelated PapersTrastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance|Molecular Cancer|2014|67